HLA-E Protects Glioma Cells from NKG2D-Mediated Immune Responses In Vitro: Implications for Immune Escape In Vivo
Open Access
- 1 June 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Neuropathology & Experimental Neurology
- Vol. 64 (6) , 523-528
Abstract
The nonclassical MHC class I molecule HLA-E is the only known ligand for CD94/NKG2A and CD94/NKG2C expressed on NK and CD8+ αβ and γδ T cells. HLA-E may transmit either activating signals via CD94/NKG2C or inhibitory signals mediated by CD94/NKG2A. Here we show that HLA-E is expressed at mRNA and protein level in human long-term glioma cell lines, primary ex vivo polyclonal glioblastoma cell cultures and surgical glioblastoma specimens. Furthermore, immunohistochemistry revealed an enhanced in vivo expression of HLA-E in gliomas of lower grades and a massive overexpression in grade IV glioblastomas compared with normal CNS tissue. An immune-inhibitory effect of HLA-E on tumor-specific CTL has already been described. We show that siRNA-mediated silencing of HLA-E or blocking of CD94/NKG2A enables NKG2D-mediated lysis of 51Cr-labeled tumor cells by NK cells. Thus, our study provides the first evidence that expression and interaction of HLA-E on cancer cells with CD94/NKG2A expressed on lymphocytes compromises innate anti-tumor immune responses.Keywords
This publication has 21 references indexed in Scilit:
- RNA Interference Targeting Transforming Growth Factor-β Enhances NKG2D-Mediated Antiglioma Immune Response, Inhibits Glioma Cell Migration and Invasiveness, and Abrogates TumorigenicityIn vivoCancer Research, 2004
- Analysis of regulatory CD8 T cells in Qa-1-deficient miceNature Immunology, 2004
- The Three Es of Cancer ImmunoeditingAnnual Review of Immunology, 2004
- The Role of CD94/NKG2 in Innate and Adaptive ImmunityImmunologic Research, 2004
- CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell deathOncogene, 2003
- IFN-γ protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanismJournal of Clinical Investigation, 2002
- Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICAScience, 1999
- NK CELL RECEPTORSAnnual Review of Immunology, 1998
- The human major histocompatibility complex class Ib molecule HLA‐E binds signal sequence‐derived peptides with primary anchor residues at positions 2 and 9European Journal of Immunology, 1997
- The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-?, T-cell apoptosis, and the immune privilege of the brainBrain Research Reviews, 1995